NASDAQ:MNMD

Mind Medicine (MindMed) Stock Forecast, Price & News

3.73
0.00 (0.00 %)
(As of 06/17/2021 03:28 PM ET)
Add
Compare
Today's Range
3.62
3.81
50-Day Range N/A
52-Week Range
0.29
5.77
Volume183,917 shs
Average Volume6.52 million shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.


About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

1104th out of 2,102 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Mind Medicine (MindMed) (NASDAQ:MNMD) Frequently Asked Questions

What stocks does MarketBeat like better than Mind Medicine (MindMed)?

Wall Street analysts have given Mind Medicine (MindMed) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mind Medicine (MindMed) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Mind Medicine (MindMed)'s key executives?

Mind Medicine (MindMed)'s management team includes the following people:
  • Mr. Jamon Alexander Rahn, Co-Founder, CEO & Director
  • Dr. Miriam Halperin Wernli, Pres & Director
  • Dr. Scott M. Freeman, Co-Founder & Clinical Advisor (Age 64, Pay $356.06k)
  • Mr. David Dean Guebert, Chief Financial Officer
  • Ms. Carol Nast, Chief Operating Officer
  • Mr. Leonard Latchman, Co-founder
  • Mr. Bradford Cross, Chief Technology Officer
  • Dr. Donald R. Gehlert Ph.D., Chief Scientific Officer & Member of Scientific Advisory Board
  • Ms. Madeline Feldman, Director of Operations & Admin.
  • Mr. Collin Gage, VP of Corp. Devel.

Who are some of Mind Medicine (MindMed)'s key competitors?

What is Mind Medicine (MindMed)'s stock symbol?

Mind Medicine (MindMed) trades on the NASDAQ under the ticker symbol "MNMD."

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mind Medicine (MindMed)'s stock price today?

One share of MNMD stock can currently be purchased for approximately 3.70.

How much money does Mind Medicine (MindMed) make?

Mind Medicine (MindMed) has a market capitalization of $1.13 billion.

How many employees does Mind Medicine (MindMed) have?

Mind Medicine (MindMed) employs 22 workers across the globe.

What is Mind Medicine (MindMed)'s official website?

The official website for Mind Medicine (MindMed) is www.mindmed.co.


This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.